Normal carcinoembryonic antigen indicates benefit from perioperative chemotherapy to gastric carcinoma patients

Figure 1 The treatment subgroups of the cohort of 228 patients in this retrospective study. CEA: Carcinoembryonic antigen; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease.

Figure 2 Survival curves for carcinoembryonic antigen patients with different treatments. A: The 228 patients in follow-up over this study; follow-up times ranged from 8 to 59 mo (median, 32 mo); B: Survival curves for the elevated carcinoembryonic antigen (CEA) patients and the normal CEA patients, with two-year survival rates of 57% and 51%, respectively, and no statistically significant difference between the groups (P = 0.740); C: Survival curves for patients receiving perioperative chemotherapy or adjuvant chemotherapy, with two-year survival rates of 58% and 50%, respectively. The difference is statistically significant (P = 0.029); D: Survival curves for the elevated CEA patients who received perioperative or adjuvant chemotherapy, with two-year survival rates of 58% and 58%, respectively, with no statistical significance (P = 0.784); E: Survival curves for normal CEA patients who received perioperative or adjuvant chemotherapy, with a two-year survival rate of 59% and 48%, respectively. The difference is statistically significant (P = 0.024).